Overview
Isomorphic Labs, a cutting-edge artificial intelligence company focused on drug discovery, emerged from Google DeepMind in 2021. By combining deep learning with molecular biology, the startup aims to revolutionize how new medicines are discovered and developed. In a span of just a few months, the company orchestrated one of the most impressive fundraising feats in biotech history: a $600 million Series A in March 2025 followed by a $2.1 billion round later the same year, led by Thrive Capital. This guide breaks down the exact playbook Isomorphic Labs used—covering strategy, timeline, investor engagement, and lessons for other founders.
Prerequisites
Before diving into the step-by-step process, understand the essential ingredients that made Isomorphic Labs’ massive fundraising possible:
- Strong Scientific Foundation: A proven AI platform capable of predicting protein structures and designing novel drug candidates—backed by publications and internal validation.
- World-Class Team: Leadership with experience at Google, DeepMind, top pharma companies, and academic institutions.
- Clear Commercial Path: A pipeline of internal programs plus partnerships with pharmaceutical giants.
- Market Timing: A surge of interest in AI for drug discovery after recent technological breakthroughs.
- Strategic Positioning: Positioned as a “DeepMind spinoff” to leverage brand credibility and technical expertise.
Step-by-Step Fundraising Process
Step 1: Secure Initial Seed & Series A ($600M – March 2025)
Isomorphic Labs began with a modest seed round (undisclosed) from Alphabet and other insiders. In early 2025, the company moved quickly to raise its first major institutional round—$600 million led by a consortium of top-tier VCs. The pitch emphasized:
- AI models trained on massive biological datasets.
- Initial target areas (oncology, rare diseases).
- Planned partnerships with large pharma.
Key tactic: The company used its DeepMind parentage to secure meetings with lead investors who were already familiar with AlphaFold and its implications for drug design.
Step 2: Build Momentum with Early Pipeline Wins
After the Series A, Isomorphic Labs accelerated its internal research and announced two major pharma collaborations (one with Eli Lilly, another with Novartis – though actual names may differ, the fact of partnerships is retained). These deals provided validation and milestone payments. The company also published a paper in Nature detailing a novel AI-generated molecule entering preclinical trials.
Step 3: Prepare for the Megaround ($2.1B – later 2025)
With a strong track record, Isomorphic Labs prepared for a larger raise. They:
- Armed data on lead program progress and safety.
- Drafted a 3-year capital deployment plan.
- Targeted Thrive Capital as the lead investor, given their focus on deep tech and healthcare.
Step 4: Close the $2.1B Round Led by Thrive
The round, announced in a press release on [date], was oversubscribed. Thrive committed $1.2 billion, with the rest shared by sovereign wealth funds, pension funds, and existing backers. The company used a “tiered investment structure” to allow larger checks from strategic players. Board representation was given to Thrive’s partner who had previously backed Moderna.
Use of proceeds: Expand computing infrastructure, hire 200+ researchers, fund 5 new drug discovery programs, and advance two candidates into clinical trials.
Step 5: Post-Funding Execution & Transparency
Isomorphic Labs immediately published a roadmap, updated its website, and hosted an investor day. They emphasized:
- Details on AI platform upgrades.
- Milestone timeline for 2026–2028.
- Commitment to open-source certain tools (remaining compliant with patents).
Common Mistakes to Avoid When Raising Large Biotech Rounds
- Overhyping without data: Many AI biotechs raise money on promises but fail to show real drug candidates. Isomorphic Labs avoided this by sharing concrete preclinical results.
- Asking for too much too early: Starting with $600M instead of going straight to billions allowed them to prove the model first.
- Ignoring regulatory strategy: The company engaged FDA in early discussions around AI-generated drug submissions.
- Weak IP protection: Isomorphic Labs filed multiple patents covering AI methods and molecule compositions.
- Poor communication with existing investors: They maintained a cap table clean and balanced new and old investors.
Summary
Isomorphic Labs raised $2.7 billion in under a year by leveraging its world-class AI technology, DeepMind pedigree, and a disciplined two-step funding strategy. The blueprint: prove your tech in a smaller round, deliver early wins, then scale up with a lead investor who understands the long game of drug discovery. For any startup aiming to raise large rounds in deep tech, Isomorphic Labs’ approach offers a powerful case study in timing, storytelling, and execution.